OverviewDosage GuideSide EffectsProtocolResultsWeight LossClinical TrialsInjection GuideGLP-3How to GetCostFDA ApprovalAvailabilityTelehealthLiver FatMuscle LossWhere to Buy
Ipamorelin Protocol Guide
A structured protocol for using Ipamorelin: cycle length, administration timing, stacking considerations, and monitoring.
Protocol Overview
Recommended Cycle Length
12–24 weeks (typical cycle)
Dosing Frequency
1–3 times daily (often before bed and/or around workouts)
Administration Route
Subcutaneous injection
Titration Required
Not typically required
Dosing Protocol
Starting dose: 100 mcg — 1–3 times daily (often before bed and/or around workouts)
Maintenance dose: 200-300 mcg — 1–3 times daily (often before bed and/or around workouts)
Commonly dosed at 200–300mcg per injection, 1–3 times daily. Best taken on an empty stomach to maximize GH pulse. Frequently combined with CJC-1295 or GHRH peptides for synergistic effect.
Stacking & Combination Protocols
Important: Stacking Ipamorelin with other active compounds significantly increases the complexity of managing side effects and monitoring. Always consult a qualified healthcare provider before combining compounds.
Commonly Discussed Combinations
CJC-1295 (GHRH analog)
Research only — widely used in practiceThe classic Ipamorelin stack. CJC-1295 (a GHRH analog) amplifies the magnitude of the GH pulse while Ipamorelin triggers the pulse. Together they produce substantially higher GH release than either peptide alone.
Synergy: Very high — primary combination
GHRP-6 or GHRP-2
Research only — anecdotal useOther GHRPs can be used alongside Ipamorelin for stronger GH stimulation. Note: GHRP-6 causes significant hunger (ghrelin activation) — often less desirable than the more selective Ipamorelin.
Synergy: Additive
Sermorelin
Research onlyAnother GHRH analog (like CJC-1295 but shorter half-life). Some practitioners use Sermorelin + Ipamorelin as an alternative to CJC-1295 + Ipamorelin. Requires more frequent dosing.
Synergy: Moderate
Do NOT Stack With
✗
Use with active cancer
Growth hormone stimulation is contraindicated in active malignancy. GH can theoretically promote tumor growth.
✗
Uncontrolled diabetes / insulin resistance
GH can worsen insulin sensitivity in the short term. Diabetic patients need close glucose monitoring if using GH secretagogues.
✗
Pituitary tumors or disorders
Any pituitary condition should be evaluated before using peptides that modulate pituitary function.
Related Peptides
bpc 157— commonly compared / discussed alongside Ipamorelin
Learn more →semaglutide— commonly compared / discussed alongside Ipamorelin
Learn more →retatrutide— commonly compared / discussed alongside Ipamorelin
Learn more →Monitoring While on Protocol
- ✓Track sleep quality and recovery scores weekly (primary benefit markers)
- ✓Note body composition changes monthly (scale + tape measure)
- ✓Check IGF-1 levels at baseline and mid-cycle if monitoring systematically
- ✓Monitor fasting glucose — GH secretion can temporarily affect insulin sensitivity
- ✓Schedule follow-up every 6–8 weeks with supervising practitioner
Exploring Retatrutide Access?
See how patients are accessing retatrutide through physician-supervised telehealth and compounding pharmacies.
Not FDA approved. Access requires physician oversight.
Affiliate links — we may earn a commission at no cost to you.
Medical Disclaimer: This protocol guide is for informational purposes only and is based on available research. It does not constitute medical advice. Work with a licensed healthcare provider to design and monitor your peptide protocol.